Fibromuscular dysplasia management guidelines

Jump to navigation Jump to search

Fibromuscular dysplasia Microchapters


Patient Information


Historical Perspective




Differentiating Fibromuscular dysplasia from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings






Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Management Guidelines

Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

ASA/ACCF/AHA Guideline Recommendations

Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries

Case Studies

Case #1

Fibromuscular dysplasia management guidelines On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Fibromuscular dysplasia management guidelines

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fibromuscular dysplasia management guidelines

CDC on Fibromuscular dysplasia management guidelines

Fibromuscular dysplasia management guidelines in the news

Blogs on Fibromuscular dysplasia management guidelines

Directions to Hospitals Treating Fibromuscular dysplasia

Risk calculators and risk factors for Fibromuscular dysplasia management guidelines

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Management Guidelines

2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS: Guidelines on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease (DO NOT EDIT)[1]

Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries (DO NOT EDIT)[1]

Class III (No Benefit)
"1. Revascularization is not recommended for patients with asymptomatic FMD (Fibro Muscular Dysplasia) of a carotid artery, regardless of the severity of stenosis. (Level of Evidence: C) "
Class IIa
"1. Annual noninvasive imaging of the carotid arteries is reasonable initially for patients with fibromuscular dysplasia (FMD) to detect changes in the extent or severity of disease, although the effect on outcomes is unclear. Studies may be repeated less frequently once stability has been confirmed. (Level of Evidence: C) "
"2. Administration of platelet-inhibitor medication can be beneficial in patients with FMD of the carotid arteries to prevent thromboembolism, but the optimum drug and dosing regimen have not been established. (Level of Evidence: C) "
"3. Carotid angioplasty with or without stenting is reasonable for patients with retinal or hemispheric cerebral ischemic symptoms related to FMD of the ipsilateral carotid artery, but comparative data addressing these methods of revascularization are not available. (Level of Evidence: C) "


  1. 1.0 1.1 Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL; et al. (2011). "2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery". Circulation. 124 (4): 489–532. doi:10.1161/CIR.0b013e31820d8d78. PMID 21282505.

Template:WH Template:WS